Coronavirus to disrupt EU pharma drug launches, analysts war...

Big European launches of drugs for cancer, HIV, and sickle cell disease could be affected by coronavirus, according to a new analysis from Jefferies.

NICE rejects Roche's Polivy combination in advanced lymphoma

England’s NHS should not fund Roche’s Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine for adults with a form of advanced lymphoma, NICE has said in first draft g

Novartis' Beovu safety woes could cost billions of dollars, ...

The launch of Novartis’ Beovu ophthalmology drug could be compromised after a safety warning from doctors over several cases of sight-threatening inflammation of blood vessels.

FDA approves 'potential blockbuster' migraine jab from Lundb...

The FDA has approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs from a new class.

US, EU reviews start for Novartis’ Ocrevus rival ofatumumab

First UK patients get Novartis’ Luxturna gene therapy for bl...